FDA approves Eli Lilly’s Verzenio for metastatic breast cancer treatment
Eli Lilly and Company (Lilly) has announced receiving U.S. Food and Drug Administration (FDA) approval for Verzenio (abemaciclib), to treat patients with metastatic breast cancer ... Read More
Lilly’s breast cancer drug abemaciclib shows promising results in phase 3 trial
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination ... Read More
Roche’s Perjeta shows significant promise in phase 3 breast cancer trial
Roche has announced promising results from the APHINITY trial, a crucial Phase 3 study evaluating Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy. This ... Read More
University of Antwerp launches pioneering clinical trial to combat cognitive deficits in breast cancer patients
The University of Antwerp in Belgium has initiated an innovative clinical trial aimed at mitigating the cognitive deficits associated with breast cancer treatment, marking a ... Read More